StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
COGTCogent Biosciences, Inc.
stockpulse.co.kr
Nasdaq
$30.43▼ 2.42%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.20BShares out 1.700M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

10
  • 10.5After-hours26.10.06 05:30
    4Ownership#●●●

    Cogent Biosciences, Inc.

    Karen Jean Ferrante, an executive at Cogent Biosciences, Inc., filed a report regarding changes in her beneficial ownership of securities effective October 1, 2026. This filing serves as a standard disclosure of insider equity transactions.…more

    $30.43-2.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.2After-hours26.09.03 05:11
    8-KKey event

    Cogent Biosciences, Inc.

    Cogent Biosciences has entered into a commercial supply agreement with Hovione FarmaCiencia for the manufacturing of bezuclastinib spray-dried dispersion and tablets. The agreement has an initial five-year term with automatic two-year renewals, requiring the company to purchase products based on quarterly rolling forecasts.…more

    $30.43-2.42%vs prev close
    View filingShare
  • 8.31After-hours26.09.01 06:01
    4Ownership

    Cogent Biosciences, Inc.

    Arlene Morris, an independent director of Cogent Biosciences, reported a change in beneficial ownership of company securities on August 27, 2026, via SEC Form 4. This filing serves as the official disclosure of the insider's updated equity holdings.…more

    $30.43-2.42%vs prev close
    View filingShare

9 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.15Pre-market26.09.15 21:00
    Bullish#●●●#●●●

    Cogent Biosciences Announces FDA Acceptance of NDA for Bezuclastinib

    Cogent Biosciences announced that the FDA has accepted its New Drug Application for bezuclastinib to treat advanced systemic mastocytosis. The agency has set a PDUFA target action date of June 29, 2027, and currently does not plan to hold an advisory committee meeting.…more

    $30.43-2.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 9.2After-hours26.09.03 05:27

    ●●●●●●●● ●●●●● ●●●●●●

    Cogent Biosciences has signed a five-year commercial supply agreement with Hovione for the manufacturing of its bezuclastinib products. The partnership ensures a stable supply chain for the company's drug candidates with automatic renewal provisions.…more

    $30.43-2.42%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →